These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 19064899)

  • 21. Antimicrobial activity of tigecycline against clinical isolates from Spanish medical centers. Second multicenter study.
    Betriu C; Rodríguez-Avial I; Gómez M; Culebras E; López F; Alvarez J; Picazo JJ;
    Diagn Microbiol Infect Dis; 2006 Dec; 56(4):437-44. PubMed ID: 16949245
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antimicrobial susceptibility trends among gram-positive and -negative clinical isolates collected between 2005 and 2012 in Mexico: results from the Tigecycline Evaluation and Surveillance Trial.
    Morfin-Otero R; Noriega ER; Dowzicky MJ
    Ann Clin Microbiol Antimicrob; 2015 Dec; 14():53. PubMed ID: 26667651
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tigecycline in vitro activity against gram-negative and gram-positive pathogens collected in Italy.
    Roveta S; Marchese A; Debbia EA
    Chemotherapy; 2008; 54(1):43-9. PubMed ID: 18073470
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antimicrobial Susceptibility among European Gram-Negative and Gram-Positive Isolates Collected as Part of the Tigecycline Evaluation and Surveillance Trial (2004-2014).
    Rodloff AC; Dowzicky MJ
    Chemotherapy; 2017; 62(1):1-11. PubMed ID: 27216271
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antimicrobial susceptibility of gram-negative and gram-positive bacteria collected from countries in Eastern Europe: results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) 2004-2010.
    Balode A; Punda-Polić V; Dowzicky MJ
    Int J Antimicrob Agents; 2013 Jun; 41(6):527-35. PubMed ID: 23590898
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antimicrobial susceptibility among gram-positive and gram-negative blood-borne pathogens collected between 2012-2016 as part of the Tigecycline Evaluation and Surveillance Trial.
    Zhang Z; Chen M; Yu Y; Pan S; Liu Y
    Antimicrob Resist Infect Control; 2018; 7():152. PubMed ID: 30564308
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases.
    Biedenbach DJ; Beach ML; Jones RN
    Diagn Microbiol Infect Dis; 2001 Aug; 40(4):173-7. PubMed ID: 11576790
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro activity of tigecycline against 2423 clinical isolates and comparison of the available interpretation breakpoints.
    Papaparaskevas J; Tzouvelekis LS; Tsakris A; Pittaras TE; Legakis NJ;
    Diagn Microbiol Infect Dis; 2010 Feb; 66(2):187-94. PubMed ID: 19836184
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Validation and reproducibility assessment of tigecycline MIC determinations by Etest.
    Bolmström A; Karlsson A; Engelhardt A; Ho P; Petersen PJ; Bradford PA; Jones CH
    J Clin Microbiol; 2007 Aug; 45(8):2474-9. PubMed ID: 17522277
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro activity of tigecycline, a new glycylcycline, tested against 1,326 clinical bacterial strains isolated from Latin America.
    Gales AC; Jones RN; Andrade SS; Pereira AS; Sader HS
    Braz J Infect Dis; 2005 Oct; 9(5):348-56. PubMed ID: 16410885
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents.
    Sader HS; Jones RN; Stilwell MG; Dowzicky MJ; Fritsche TR
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):181-6. PubMed ID: 16105562
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A longitudinal analysis of antimicrobial susceptibility in clinical institutions in Germany as part of the Tigecycline Evaluation and Surveillance Trial (2004-2007).
    Seifert H; Dowzicky MJ
    Chemotherapy; 2009; 55(4):241-52. PubMed ID: 19468222
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antimicrobial activity against a global collection of skin and skin structure pathogens: results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.), 2010-2014.
    Tärnberg M; Nilsson LE; Dowzicky MJ
    Int J Infect Dis; 2016 Aug; 49():141-8. PubMed ID: 27343986
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004).
    Hoban DJ; Bouchillon SK; Johnson BM; Johnson JL; Dowzicky MJ;
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):215-27. PubMed ID: 16105567
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rates of antimicrobial resistance in Latin America (2004-2007) and in vitro activity of the glycylcycline tigecycline and of other antibiotics.
    Rossi F; García P; Ronzon B; Curcio D; Dowzicky MJ
    Braz J Infect Dis; 2008 Oct; 12(5):405-15. PubMed ID: 19219281
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The ribosomal S10 protein is a general target for decreased tigecycline susceptibility.
    Beabout K; Hammerstrom TG; Perez AM; Magalhães BF; Prater AG; Clements TP; Arias CA; Saxer G; Shamoo Y
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5561-6. PubMed ID: 26124155
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.
    Sader HS; Jones RN; Dowzicky MJ; Fritsche TR
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro antibacterial activity of tigecycline against resistant Gram-negative bacilli and enterococci by time-kill assay.
    Pankey GA; Ashcraft DS
    Diagn Microbiol Infect Dis; 2009 Jul; 64(3):300-4. PubMed ID: 19501791
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antimicrobial susceptibility among gram-negative isolates collected from intensive care units in North America, Europe, the Asia-Pacific Rim, Latin America, the Middle East, and Africa between 2004 and 2009 as part of the Tigecycline Evaluation and Surveillance Trial.
    Bertrand X; Dowzicky MJ
    Clin Ther; 2012 Jan; 34(1):124-37. PubMed ID: 22154196
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Susceptibility of common aerobic pathogens to tigecycline: results of a surveillance study in Germany.
    Kresken M; Leitner E; Brauers J; Geiss HK; Halle E; von Eiff C; Peters G; Seifert H;
    Eur J Clin Microbiol Infect Dis; 2009 Jan; 28(1):83-90. PubMed ID: 18716808
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.